Study identifier:NIS-NFR-XXX-2012/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Evaluation of sub-syndromal symptoms after acute depressive episode in bipolar disorder
Bipolar Disorder
N/A
No
-
All
125
Observational
18 Years - 150 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Mar 2015 by AstraZeneca
AstraZeneca
-
The study aims to evaluate: - the frequency of subsyndromal symptoms or disorders observed during interepisode phases in bipolar patients, particularly after a depressive episode in which these subsyndromal disorders are the most frequent - the functional impact of these disorders, factors or symptom thresholds associated with functional remission, and factors associated with symptomatic remission over a sufficient follow-up (12 months).
Evaluation of sub-syndromal symptoms after acute depressive episode in bipolar disorder
Location
Location
AIX EN PROVENCE, France
Location
AJACCIO, France
Location
ALTKIRCH, France
Location
ARMENTIERES, France
Location
AVIGNON, France
Location
BAILLEUL, France
Location
BOHARS, France
Location
BORDEAUX, France
Arms | Assigned Interventions |
---|---|
Bipolar disorder patients | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.